Summary by Moomoo AI
Biora Therapeutics, a clinical-stage biotechnology company, has reported its financial performance and business developments in its latest annual report. The company, which trades under the symbol 'BIOR' on Nasdaq, has not paid dividends and does not expect to do so in the foreseeable future due to reinvestment in operations and research and development. Biora Therapeutics has undergone a 1-for-25 reverse stock split, reducing its authorized shares from 350 million to 164 million. The company's financial performance shows a net loss of $124.1 million for the year ended December 31, 2023, which is an increase from the $38.2 million net loss in the previous year. Research and development expenses rose by $5.8 million, while selling, general, and administrative expenses saw a slight decrease of $0.7 million. The...Show More